Clinical trials: COVID-19; Immunity
SARS-CoV-2 Infection
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) Based on Different COVID-19 Inactivated Vaccine in Adults Aged 18 Years and Above
To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 3, 4, 5, or 6 months since finished two doses schedule…
- Trial name
- NCT05163652
- Testing
- SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
- Where
- China
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
Healthy Volunteer
Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine
Background: Vaccines help prevent disease by causing the body to have an immune response. Many parts of this response happen in the blood. This response happens over days and weeks after getting the vaccine.
- Trial name
- NCT04025580
- Testing
- Flucelvax, Fluvirin, Fluzone High Dose
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diseases, Chronic, Covid19
Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease
On 11 February 2020, the International Committee for the Classification of Viruses named the disease caused by SAＲS-CoV-2 infection in humans as the new coronavirus pneumonia (coronavirus disease 2019, COVID-19).Due to the…
- Conditions
- Diseases, Chronic, Covid19, Adverse Reaction to Vaccine
- Trial name
- SIM-PBD (NCT05043246)
- Testing
- SARS-COV-2 VACCINE
- Where
- China
- Volunteers
- 2,300 people, healthy volunteers welcome
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
COVID-19
Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain
The United Arab Emirates (UAE), the Kingdom of Bahrain, Kuwait, Oman, and Qatar have authorised sotrovimab for emergency use. Local experience among physicians include recent successful COVID-19 vaccine pivotal studies supported…
- Trial name
- NCT05398718
- Testing
- Sotrovimab
- Where
- Bahrain
- Volunteers
- 20,000 people
- Sponsor
- Abu Dhabi Health Services Company
SARS-CoV 2, COVID
Precision Immunology to Determine the Immune Response in Patients With COVID-19
To better understand the immune response to SARS-CoV-2 infection, we devised a precision immunology approach to systematically study the immune function of different patient cohorts
- Trial name
- NCT04360733
- Testing
- Blood draw
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Bonn
SARS-CoV-2, Vaccine
COVID-19 Vaccine Induced Adaptive Immune Responses
The coronavirus disease 2019 (COVID-19) caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)，resulting in more than 82 million confirmed cases and caused around 1.8 million deaths, as of 2…
- Conditions
- SARS-CoV-2, Vaccine, COVID-19
- Trial name
- NCT04729374
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Immune Response, Safety
Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines
The goal is to evaluate the immunogenicity and safety of coadministration of a bivalent BA.4/BA.5-adapted COVID-19 booster vaccine, and influenza vaccine among healthy adults during 2022-23 season.
- Trial name
- NCT05970887
- Testing
- bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine, quadrivalent influenza vaccine
- Where
- South Korea
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Catholic Kwandong University
Vaccination; Infection, Covid19
Immune Response to Vaccination Against Covid-19, a Follow up Study
The study investigates the immune response after vaccination in individuals with and without pre-existing immunity to Coronavirus disease (COVID) -19. The participants are followed and sampled up to 4 years after vaccination.
- Trial name
- CoVacc (NCT04920357)
- Testing
- Vaccination
- Where
- 5 sites in Sweden
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Umeå University
COVID-19 Vaccination
RCT of Mushroom Based Natural Product to Enhance Immune Response to COVID-19 Vaccination
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), for use as an adjunct to vaccination for COVID-19 in a…
- Trial name
- MACH19 (NCT04951336)
- Testing
- FoTv
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
COVID-19, SARS-CoV-2 Infection
COVID-19: SARS-CoV-2-CZ-PREVAL-II Study
The aim of the SARS-CoV-2-CZ-PREVAL-II Study is to quantify the prevalence of participants with antibodies against SARS-CoV-2 and/or cell immunity against SARS-CoV-2 in specific subjects cohorts.
- Trial name
- NCT05096962
- Testing
- Quantitative analysis of SARS-CoV-2 antibodies, Cellular immunity
- Where
- Czechia
- Volunteers
- 7,268 people, healthy volunteers welcome
- Sponsor
- Institute of Health Information and Statistics of the Czech Republic
SARS-CoV-2 Infection, COVID-19
A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
This is a study to evaluate the efficacy, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults aged 18-84 years in the United Kingdom.
- Trial name
- NCT04583995
- Testing
- SARS-CoV-2 rS/Matrix M1-Adjuvant, Licensed seasonal influenza vaccine
- Where
- 33 sites in United Kingdom
- Volunteers
- 15,185 people, healthy volunteers welcome
- Sponsor
- Novavax
Cancer
Mechanisms of Anti COVID-19 Humoral and Cellular Immune Response After Vaccination in a Sample of Patients and Salaried Staff From a French Anti-cancer Center
Special populations are people with a risk to dévelop severe forms of a disease. The immunogenicity and efficacy of vaccines in this population may be different compared of the general population.
- Trial name
- CANSEROVAX (NCT04935528)
- Testing
- serology and ELISPOT test, serology
- Where
- France
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Centre Georges Francois Leclerc
Immunity, Vaccine Reaction
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
The immune system response needs to be forceful but also balanced for a rapid recovery from infection which avoids harmful overreactions.
- Conditions
- Immunity, Vaccine Reaction, Influenza, Covid19
- Trial name
- NCT04798677
- Testing
- ABBC1 Immunoessential
- Where
- Spain
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AB Biotek
COVID-19
The Effect of Helminth Infection Plus COVID-19 Infection on the Immune Response and Intestinal Microorganisms
This is a pilot, cross-sectional, sample collection study to characterize the immune response and intestinal microorganisms in people with and without COVID-19 antibodies and helminth infection.
- Trial name
- NCT04813328
- Where
- India
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS CoV 2 Infection, COVID-19
Humoral and Cellular Immunity in First-cycle SARS-CoV-2 Vaccinated COVID-19 Patients
Infection by the recent Coronavirus (SARS-CoV-2) has generated at a pandemic level a new pathology, called COVID-19, characterized by "flu-like" symptoms up to severe acute respiratory failure.
- Trial name
- NCT05338736
- Testing
- LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin), LIAISON SARS-CoV2-IgM (DiaSorin), Human IFN-g ELISpot PLUS (ALP) (AUROGENE)
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University Magna Graecia
Covid19, Immune Response
Aerobic Versus Anaerobic Exercise on Immune Functions and Disease Severity in Patients With COVID-19
Participants were assigned randomly into two groups, aerobic exercise and resistance exercise groups. All participants in both groups followed the WHO guidelines of quarantine and used standardized medications given by the…
- Trial name
- NCT05000008
- Testing
- Exercises
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul Gelisim University
Covid19
Characterisation of the Immune Response to SARS-CoV-2 / COVID-19
Emerging clinical details of the current SARS-CoV-2 pandemic have illustrated that there are multiple clinical presentations and outcomes of this viral infection.
- Trial name
- NCT04729452
- Testing
- blood test
- Where
- United Kingdom
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Cwm Taf University Health Board (NHS)
Covid19
Using Travelan to Boost Immune Response in Vitro to COVID-19
The gut immune system was shown as an effective target for inducing systemic immune signals against viruses. Oral administration of Travelan, an over the counter product which contains hyperimmune bovine colostrum was shown in…
- Trial name
- NCT04643561
- Testing
- Travelan OTC
- Where
- Israel
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
SARS-CoV-2
Screening for COVID-19 and Monitoring of Serological Responses to SARS-CoV-2 in Healthcare Workers
The main objectives of this study are 1) to establish the prevalence of SARS-CoV-2 in asymptomatic healthcare workers (HCWs) in an early phase of community spread as well as 2) to monitor the future spread of the disease by…
- Trial name
- SeCo (NCT04370119)
- Testing
- Nasal swab, Serum testing
- Where
- Germany
- Volunteers
- 1,092 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald
Covid19, Oncologic Disorders
COVID-19 Vaccination in Oncologic Patients
Evaluating the vaccination willingness in oncologic patients over six months as well as estimating the effects of radiotherapy/systemic anticancer treatment on the efficacy and toxicity of currently approved SARS-CoV-2 vaccines
- Trial name
- VINCI (NCT04918888)
- Where
- 2 sites in Austria
- Volunteers
- 1,150 people
- Sponsor
- Krankenhaus Barmherzige Schwestern Linz